Quick Answer
Advanced prostate cancer does not always mean the same thing as metastatic prostate cancer. “Locally advanced” cancer has grown beyond the prostate into nearby tissues and/or regional lymph nodes but may still have no distant metastases. “Metastatic” prostate cancer has spread to distant lymph nodes, bone or other organs.
Possible symptoms of advanced disease include worsening urinary obstruction, blood in urine or semen, fatigue, unintentional weight loss, erectile problems, persistent bone pain and fractures. But advanced prostate cancer can also progress with few or no symptoms, which is why follow-up relies on PSA, clinical assessment and imaging—not symptoms alone.
New severe back pain with leg weakness, numbness, difficulty walking, or loss of bladder/bowel control is an emergency. These can be signs of metastatic spinal-cord compression and need urgent assessment.
Modern treatment is much broader than “radiation, chemotherapy or hormone therapy.” Depending on disease state and biomarkers, treatment may include androgen-deprivation therapy (ADT), androgen-receptor pathway inhibitors, docetaxel, radiotherapy, PARP-targeted treatment, PSMA-directed radioligand therapy, radium-223, bone-protective therapy and supportive/palliative care.
What Does “Advanced Prostate Cancer” Actually Mean?
The term advanced prostate cancer is sometimes used loosely, so it is important to clarify the stage.
Locally Advanced Prostate Cancer
Locally advanced disease has grown outside the prostate into nearby tissue and/or regional lymph nodes but has not necessarily spread to distant organs.
Examples include cancer extending into the seminal vesicles or nearby structures and some cancers involving pelvic lymph nodes.
Metastatic Prostate Cancer
Metastatic prostate cancer has spread to distant sites. Common locations include:
- bones, particularly the spine and pelvis;
- distant lymph nodes;
- liver; and
- lungs.
See our detailed prostate cancer stages and metastasis guide.
Does Advanced Prostate Cancer Always Cause Symptoms?
No.
Metastatic cancer can sometimes be found on PSA follow-up or imaging before the patient notices a new symptom.
When symptoms do occur, they depend on:
- where the cancer has spread;
- how much cancer is present;
- whether it is obstructing the urinary tract;
- whether bone or bone marrow is involved; and
- the effects of previous or current treatments.
Possible Symptoms of Advanced Prostate Cancer
| Possible symptom | What it may indicate | Important note |
|---|---|---|
| Persistent bone pain | Bone metastases, commonly spine, pelvis, ribs or long bones. | Most ordinary back or joint pain is not cancer, but new persistent unexplained pain needs assessment in someone with prostate cancer. |
| Fracture after minor trauma | Bone weakened by metastasis or osteoporosis. | ADT itself can also weaken bone over time. |
| Weakness, numbness or walking difficulty | Possible spinal-cord or nerve-root compression. | This can be an oncologic emergency. |
| Loss of bladder/bowel control | Possible spinal-cord compression. | Seek emergency care. |
| Difficulty urinating or retention | Local tumor growth, prostate obstruction, treatment effects or another urinary disorder. | BPH can cause the same symptoms. |
| Blood in urine or semen | Can occur with local tumor involvement. | Also occurs with infection, BPH and procedures. |
| Fatigue / weakness | Cancer burden, anemia, treatment effects, sleep problems or other illness. | Fatigue alone is nonspecific. |
| Unintentional weight loss | Can occur with advanced cancer. | Needs investigation rather than assuming cancer progression. |
| Leg swelling | Can occur with pelvic lymph-node obstruction or a blood clot. | Sudden one-sided swelling needs prompt assessment. |
Bone Pain and Bone Metastases
Bone is one of the most common sites of metastatic prostate cancer.
Bone metastases can:
- cause persistent pain;
- weaken bone and increase fracture risk;
- compress nerves or the spinal cord; and
- occasionally contribute to abnormal blood calcium levels.
Pain from bone metastases may initially come and go and can later become more constant.
There are many ways to treat bone-related symptoms, including systemic prostate-cancer therapy, pain medicines, focused radiation and, in selected patients, bone-targeted treatment.
Spinal-Cord Compression: Know the Emergency Signs
- new severe or rapidly worsening back or neck pain;
- pain shooting down one or both legs;
- new numbness or altered sensation in the legs or abdomen;
- leg weakness;
- difficulty standing or walking;
- new inability to urinate; or
- new loss of bladder or bowel control.
Metastatic spinal-cord compression can cause permanent paralysis if treatment is delayed.
Urgent MRI is commonly required when spinal-cord compression is suspected, and treatment may include corticosteroids, radiotherapy and/or surgery depending on the individual situation.
Can Advanced Prostate Cancer Affect the Bone Marrow?
Yes, in some patients with extensive skeletal disease, prostate cancer can infiltrate the bone marrow.
This may contribute to:
- anemia;
- fatigue;
- low platelets;
- easy bruising or bleeding; or
- other abnormalities in the complete blood count.
However, fatigue in a patient with prostate cancer should not automatically be labeled as marrow invasion. ADT, chemotherapy, anemia from other causes, pain, poor sleep, infection and other conditions are also common causes.
Are Urinary Symptoms a Reliable Sign That Cancer Has Become Advanced?
No.
Difficulty urinating, a weak stream, frequency and nocturia are very common in BPH.
A man who already has prostate cancer can also have BPH, infection, bladder dysfunction or treatment-related urinary problems.
Therefore, worsening urinary symptoms should be assessed rather than assumed to prove cancer progression.
What About Erectile Dysfunction?
Erectile dysfunction can occur in men with advanced prostate cancer, but it may also result from:
- age and vascular disease;
- diabetes;
- androgen-deprivation therapy;
- previous prostate surgery;
- pelvic radiotherapy;
- medications; and
- psychological distress.
ED is therefore not a reliable marker of metastatic disease by itself.
How Do Doctors Determine Whether Prostate Cancer Has Progressed?
Symptoms are only one part of the assessment.
Depending on the clinical situation, follow-up may include:
- PSA trend;
- testosterone level, especially when assessing castration-resistant disease;
- complete blood count;
- kidney and liver tests;
- alkaline phosphatase and other bone-related laboratory markers;
- CT or MRI;
- bone scan;
- PSMA PET/CT in appropriate settings; and
- molecular/genetic testing when it may change treatment.
What Is Metastatic Hormone-Sensitive Prostate Cancer?
This means prostate cancer has spread beyond the prostate but still responds to lowering or blocking androgen signaling.
Modern treatment usually begins with androgen-deprivation therapy (ADT), but ADT alone is no longer the preferred approach for most medically fit men with newly diagnosed metastatic disease.
Depending on disease volume, overall health and molecular features, treatment may combine ADT with an androgen-receptor pathway inhibitor such as:
- abiraterone plus prednisone/prednisolone;
- apalutamide;
- enzalutamide; or
- darolutamide.
Selected medically fit patients may also receive docetaxel as part of intensified combination therapy.
For some patients with newly diagnosed low-volume metastatic disease, radiotherapy to the prostate itself can improve outcomes.
What Is Metastatic Castration-Resistant Prostate Cancer (mCRPC)?
mCRPC means the cancer is progressing despite testosterone being suppressed to castrate levels.
Importantly, ADT is generally continued even when the cancer becomes castration-resistant.
Depending on previous treatment, symptoms, metastatic sites and biomarkers, options may include:
- androgen-receptor pathway therapies;
- docetaxel or cabazitaxel chemotherapy;
- PARP inhibitors for selected DNA-repair gene alterations;
- PSMA-targeted radioligand therapy;
- radium-223 in selected men with symptomatic bone-predominant disease;
- sipuleucel-T in selected minimally symptomatic patients; and
- clinical trials.
PSMA-Targeted Radioligand Therapy Has Expanded
Lutetium-177 vipivotide tetraxetan (Pluvicto) delivers radiation to PSMA-expressing prostate-cancer cells.
The FDA expanded its mCRPC indication in March 2025 to include selected PSMA-positive patients who had received an androgen-receptor pathway inhibitor and were considered appropriate to delay taxane chemotherapy.
In July 2026, the FDA also approved Pluvicto in combination with androgen-receptor pathway inhibitor therapy for selected adults with PSMA-positive metastatic androgen pathway modulation-naïve/sensitive prostate cancer.
This is an example of how rapidly treatment for metastatic prostate cancer is changing and why an advanced-cancer article should not present chemotherapy and traditional hormone therapy as the only systemic options.
Why Genetic and Molecular Testing Matters
Modern advanced prostate-cancer treatment increasingly depends on tumor biology.
Testing may identify alterations such as:
- BRCA1 or BRCA2;
- other homologous-recombination repair genes;
- mismatch-repair deficiency / microsatellite instability; and
- other actionable pathways.
These results can influence eligibility for targeted drugs such as PARP inhibitors and may also have implications for relatives when a hereditary mutation is found.
How Are Bone Metastases Treated?
Treating the prostate cancer systemically is the foundation, but individual bone complications may need additional therapy.
Radiotherapy
External-beam radiation can be very effective for painful bone metastases and can also be used urgently in selected spinal lesions.
Zoledronic Acid and Denosumab
For selected men—particularly those with metastatic castration-resistant prostate cancer involving bone—bone-targeted agents such as zoledronic acid or denosumab can reduce skeletal complications.
These medicines require attention to:
- kidney function, particularly with zoledronic acid;
- calcium and vitamin D;
- low blood calcium; and
- the rare but serious risk of osteonecrosis of the jaw.
A dental assessment is often considered before long-term potent bone-targeted therapy.
What About Radium-223?
Radium-223 is a radiopharmaceutical that targets areas of increased bone turnover.
It can be used in selected men with metastatic castration-resistant prostate cancer involving bone, particularly when the disease is symptomatic and there are no known visceral metastases that would make it inappropriate.
It is not simply a general painkiller and should be selected within an oncology treatment plan.
What Should You Do When New Symptoms Appear?
- Contact your oncology/urology team. Do not wait for the next routine appointment if symptoms are new, persistent or rapidly worsening.
- Describe exactly when the symptom started, its location and whether it is progressing.
- Report neurological symptoms immediately—especially leg weakness, numbness, walking difficulty or bladder/bowel changes.
- Do not rely on PSA alone to decide whether a symptom represents progression.
- Ask whether new blood tests or imaging are needed.
- Review your current cancer treatment, pain control, bone health and treatment side effects.
Should Treatment Be Changed Every Time a New Symptom Appears?
No.
A new symptom first needs a diagnosis.
For example:
- back pain may be muscular rather than metastatic;
- urinary frequency may be BPH or infection;
- fatigue may be anemia or an ADT effect;
- leg swelling may be lymphatic obstruction or a blood clot; and
- weight loss may have several possible causes.
If testing confirms cancer progression, the next treatment depends on the disease state and everything the patient has already received.
Nutrition: Do You Need Extra Milk, Eggs, Cheese and Calories?
Not every man with advanced prostate cancer needs a high-calorie diet.
Nutrition should be individualized.
If a person is losing weight unintentionally, eating poorly or losing muscle mass, a dietitian may recommend:
- adequate protein;
- energy-dense foods;
- smaller frequent meals;
- oral nutrition supplements when needed; and
- ways to manage nausea, taste changes, swallowing problems or treatment-related bowel symptoms.
But many men on long-term ADT have the opposite metabolic problem: increased body fat, reduced muscle mass, insulin resistance and cardiovascular risk.
For them, indiscriminately adding large amounts of calories, cheese or high-fat foods may be unhelpful.
Exercise Still Matters in Advanced Prostate Cancer
When medically safe, regular physical activity can help maintain:
- muscle strength;
- bone health;
- balance;
- cardiovascular fitness;
- energy; and
- quality of life during ADT.
Exercise needs modification when bone metastases create a fracture risk. A physiotherapist or cancer-exercise specialist can help choose safe activities.
Supportive and Palliative Care Are Part of Treatment
Palliative care is not the same as giving up cancer treatment.
It can be introduced alongside active cancer therapy to help manage:
- pain;
- fatigue;
- urinary symptoms;
- hot flashes and hormonal side effects;
- sleep problems;
- anxiety and low mood;
- nutrition problems;
- sexual-health concerns; and
- family/caregiver burden.
Early symptom control can improve daily function and quality of life.
Coping With an Advanced Diagnosis
Fear, anger, sadness, uncertainty and changes in family roles are common after an advanced-cancer diagnosis.
Useful support may include:
- clear discussions with the oncology team;
- bringing a family member or trusted person to appointments;
- cancer support groups;
- psychological or psycho-oncology support;
- specialist palliative-care teams; and
- practical help with transport, medications and daily tasks.
No patient needs to approach advanced cancer as a test of willpower. Symptoms, treatment side effects and emotional distress are medical issues that deserve treatment and support.
Questions to Ask Your Oncologist
- Is my cancer locally advanced or metastatic?
- Where exactly has it spread?
- Is it still hormone-sensitive or is it castration-resistant?
- What is my current PSA trend and testosterone level?
- Do I need PSMA PET/CT, CT/MRI or bone imaging?
- Have germline and tumor genomic tests been performed?
- Should my treatment be intensified or changed?
- Am I eligible for a PARP inhibitor, Pluvicto, radium-223 or another targeted treatment?
- Do I need bone-protective therapy?
- What symptoms should make me contact you immediately?
- Would palliative-care or dietitian support help me now?
If you or someone you care for already has prostate cancer and develops new persistent pain, worsening urinary problems, marked fatigue, weight loss or a neurological symptom, report it to the cancer team. Do not wait for symptoms to become severe before asking for assessment.
At the same time, remember that a new symptom does not automatically mean the cancer has spread. Imaging and clinical evaluation are needed to identify the cause.
The most urgent warning is new back pain with leg weakness, numbness, difficulty walking or bladder/bowel changes. That can signal spinal-cord compression and requires emergency assessment.
Treatment for advanced prostate cancer has changed substantially. Modern care increasingly combines hormonal therapy with additional systemic treatments and uses biomarkers, PSMA imaging and genomic information to select therapies.
Dr. Albana Greca, MD, MMedSc
Family Physician / General Practitioner
Founder & Lead Medical Author, Prostate Treatment Options
Medical References
European Association of Urology. 2026 Guidelines on Prostate Cancer and 2026 EAU patient information: locally advanced and advanced/metastatic prostate cancer.
National Cancer Institute. Prostate Cancer Treatment (PDQ); Metastatic Cancer; Hormone Therapy for Prostate Cancer.
American Cancer Society. Prostate Cancer Signs and Symptoms; Treatments for Prostate Cancer Spread to Bones; Bone Metastases.
U.S. Food and Drug Administration. Pluvicto indication expansion for PSMA-positive metastatic castration-resistant prostate cancer, March 28, 2025; approval in combination with androgen-receptor pathway inhibitor therapy for selected PSMA-positive metastatic androgen pathway modulation-naïve/sensitive prostate cancer, July 31, 2026.
Last evidence update: September 2026.
Medical information notice: This article is for general education and does not replace individualized oncology care. Advanced prostate cancer is highly variable, and treatment selection depends on disease stage, prior therapy, molecular findings, symptoms and overall health.